TL;DR
Approval changes the insurance program as much as it changes the company. Clinical trial liability gives way to commercial products liability, distribution partners impose their own insurance schedules, recall becomes a real balance-sheet question, and inventory, property, and transit values rise. Start six to nine months before the PDUFA date or clearance so the program is bound, endorsed, and certificated before the first shipment.
Approaching approval or clearance
A clinical-stage program is built around trials, a lab, and a small team. A commercial program has to satisfy wholesalers, specialty pharmacies, 3PLs, GPOs, and foreign distributors, each with a contract schedule that must be met before product moves.
This page is for drug and device companies inside the final year before launch, and for the CDMO partners whose supply agreements change when the sponsor goes commercial.
Launch shift 01 · Clinical to commercial products
Clinical trial liability responds to injury to trial participants in defined studies. A commercial product creates exposure to every patient who receives it, along with prescribers, pharmacies, and distribution partners. That requires a commercial products liability program, underwritten on the label, the safety database, the manufacturing chain, and projected sales.
Two structural points deserve early attention: whether the products aggregate is shared with the general liability program or dedicated, and whether a product-specific aggregate is available or required so one product's claims do not exhaust cover for the rest of the portfolio. Trials that continue post-approval keep their own clinical coverage.
Launch shift 02 · Distribution contracts
Distribution agreements typically require specific products limits, additional insured status for completed operations, a vendors endorsement, primary and non-contributory wording, waivers of subrogation, and notice of cancellation. Device makers add GPO and hospital purchasing requirements. 3PL agreements frequently limit the warehouse's liability for stored goods, leaving the manufacturer to insure its own inventory.
The review reads each agreement's insurance and indemnity clauses during negotiation, consolidates them into one required program, and flags terms worth pushing back on before signature. Standard vendor forms carry exclusions for relabeling and repackaging, so the endorsement has to match what each partner actually does.
Launch shift 03 · Recall and contamination
Withdrawal costs - customer notification, retrieval, destruction, replacement product, and lost gross profit - are typically excluded from products liability. Separate recall or product contamination coverage addresses them, with terms that differ on what triggers coverage (a government-mandated recall, a voluntary recall, or a contamination event) and whether third-party recall costs are included.
Whether to buy it is a judgment about the product, the manufacturing chain, partner requirements, and the balance sheet. The review sets out the exposure and the options rather than assuming the answer.
Launch shift 04 · Scale, territory and timing
Commercial inventory at a CDMO, a 3PL, and in transit raises property and stock values well above clinical-supply levels. Temperature-controlled product needs cargo and stock coverage with spoilage terms that match the cold chain. General liability and umbrella limits are usually revisited at the same time as the products tower.
International distribution adds territory questions: whether the products policy covers suits brought outside the US, whether local admitted policies are required in specific countries, and how a controlled master program coordinates them. Each of these takes underwriting time, which is why the work should start six to nine months before approval.
Carrier access
Commercial products liability for drugs and devices is underwritten on details that general commercial markets do not evaluate well: indication and patient population, the safety database, labeling, manufacturing partners, and distribution model. Specialty life-sciences markets write this exposure as a core line and can coordinate products, recall, cargo, and international coverage in one program.
For CDMOs, the same markets understand how a sponsor's commercial supply agreement changes the manufacturer's exposure, and can structure limits and recall allocation to match it.
Programs anchored in Texas with broader placement across the major US life-sciences clusters - including the New Jersey pharma corridor and the North Carolina (RTP) cluster.
Frequently asked
No. Clinical trial liability is written for injury to trial participants arising from a defined study or set of studies. Once product is sold commercially, the exposure is to patients, prescribers, and distribution partners under products liability law, and that requires a commercial products liability program. Many companies carry both for a period, because trials often continue after approval.
Roughly six to nine months before the expected PDUFA date or device clearance. Wholesaler, specialty pharmacy, and 3PL agreements are usually negotiated well before launch, and their insurance clauses need to be reviewed while terms are still open. Underwriters also need time to review labeling, the safety database, manufacturing arrangements, and the distribution plan.
Requirements vary by counterparty, but commonly include commercial products liability at specified limits, additional insured status for products-completed operations, a vendors endorsement, primary and non-contributory wording, waiver of subrogation, and notice of cancellation. Some also ask for recall coverage or evidence of financial strength ratings. The specific schedule in each agreement is what governs.
An endorsement to the manufacturer's products liability policy that extends coverage to distributors and resellers for claims arising from the manufacturer's product in the normal course of their business. Standard vendor forms contain exclusions, such as for relabeling, repackaging, or products the vendor alters, so the wording should be checked against what the distributor actually does.
Generally not. Products liability responds to bodily injury and property damage claims. The cost of withdrawing product from the market - notification, retrieval, destruction, replacement, and related business interruption - is typically excluded and is addressed by separate product recall or product contamination coverage. Whether that coverage makes sense depends on the product, the supply chain, and what partners require.
The sponsor's supply agreement usually replaces or supplements the clinical supply terms, with higher products limits, broader additional insured obligations, and often recall cost allocation. Commercial volume can also change property values, inventory on hand, and transit exposure. A CDMO should read the commercial supply agreement's insurance and indemnity clauses before signing, not at the next renewal.
Next steps
Paste a distribution or supply agreement insurance section and see what it requires.
OpenHow to size the products tower against the strictest contract in your portfolio.
OpenHow recall and contamination coverage is structured for manufacturers.
OpenRecall activity across life-sciences product categories, from FDA sources.
OpenWhy operators choose this practice
Every placement passes through specialty life-sciences underwriters - not a general manufacturer or healthcare desk.
Programs placed nationally with deep practice content for the 16 states anchoring the major US life-sciences clusters.
Coverage review requests come back the same business day. MSA reads are typically half an hour or less.
Free MSA Decoder, 49-clause glossary, 60+ Q&A library. Designed for CFOs, GCs, and Quality leaders.
Related deep-dives
Complimentary launch review
Current policies, expected approval or clearance date, and the distribution, 3PL, and supply agreements in negotiation. A specialist returns a written read of what the commercial program has to satisfy and when, with no obligation to move the placement.